• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全肺灌洗成功治疗新型冠状病毒肺炎后并发的肺泡蛋白沉积症:1例罕见病例报告

Post-COVID-19 Pulmonary Alveolar Proteinosis Treated Successfully with Whole Lung Lavage: A Rare Case Report.

作者信息

Le-Khac Bao, Tran-Le Quoc-Khanh, Nguyen-Ho Lam, Duong-Quy Sy

机构信息

Department of Internal Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.

Respiratory Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam.

出版信息

Pulm Ther. 2023 Jun;9(2):287-293. doi: 10.1007/s41030-023-00224-0. Epub 2023 May 11.

DOI:10.1007/s41030-023-00224-0
PMID:37166705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10173208/
Abstract

Pulmonary alveolar proteinosis (PAP) is an uncommon disease and its diagnosis remains challenging. During the COVID-19 pandemic, it has been difficult to distinguish between PAP and post-COVID-19 pulmonary sequelae. Here we present a case of a 44-year-old male patient who experienced exertional dyspnea after recovering from COVID-19. He was initially diagnosed with post-COVID-19 syndrome and treated with systemic corticosteroid without improvement. Chest computed tomography (CT) showed crazy-paving pattern with ground-glass opacities. Fibreoptic bronchoscopy with bronchial lavage fluid (BLF) analysis confirmed the final diagnosis of PAP. The patient underwent left lung lavage in combination with conventional therapy and experienced significant improvement in his respiratory condition and overall health during follow-up. Hence, PAP could occur after a COVID-19 infection. This case highlights the importance of considering PAP as a potential diagnosis in patients with persistent respiratory symptoms after COVID-19. The high suspicion indicators of PAP revealed by chest-CT and BLF may be a key to differentiating PAP from post-COVID-19 pulmonary sequelae. Moreover, it is plausible that SARS-CoV-2 plays a role in the development of proteinosis, either by inducing a flare-up or by directly causing the condition.

摘要

肺泡蛋白沉积症(PAP)是一种罕见疾病,其诊断仍然具有挑战性。在新冠疫情期间,很难区分PAP和新冠后肺部后遗症。在此,我们报告一例44岁男性患者,他在新冠康复后出现劳力性呼吸困难。他最初被诊断为新冠后综合征,并接受全身糖皮质激素治疗,但病情无改善。胸部计算机断层扫描(CT)显示有磨玻璃影的铺路石样表现。纤维支气管镜检查及支气管肺泡灌洗(BAL)液分析确诊为PAP。患者接受了左肺灌洗联合传统治疗,随访期间呼吸状况和整体健康状况有显著改善。因此,PAP可在新冠感染后发生。该病例强调了在新冠后持续有呼吸道症状的患者中考虑PAP作为潜在诊断的重要性。胸部CT和BAL显示的PAP高疑似指标可能是区分PAP与新冠后肺部后遗症的关键。此外,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)通过诱发病情加重或直接导致该病,在蛋白沉积症的发生发展中发挥作用这一说法似乎是合理的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b971/10203069/81dd77e89f68/41030_2023_224_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b971/10203069/ddbbf34bad05/41030_2023_224_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b971/10203069/2385cbc27ac3/41030_2023_224_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b971/10203069/2d5ff322e341/41030_2023_224_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b971/10203069/81dd77e89f68/41030_2023_224_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b971/10203069/ddbbf34bad05/41030_2023_224_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b971/10203069/2385cbc27ac3/41030_2023_224_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b971/10203069/2d5ff322e341/41030_2023_224_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b971/10203069/81dd77e89f68/41030_2023_224_Fig4_HTML.jpg

相似文献

1
Post-COVID-19 Pulmonary Alveolar Proteinosis Treated Successfully with Whole Lung Lavage: A Rare Case Report.全肺灌洗成功治疗新型冠状病毒肺炎后并发的肺泡蛋白沉积症:1例罕见病例报告
Pulm Ther. 2023 Jun;9(2):287-293. doi: 10.1007/s41030-023-00224-0. Epub 2023 May 11.
2
COVID-19 and severe pulmonary alveolar proteinosis (PAP): A case report.新型冠状病毒肺炎与重症肺泡蛋白沉积症:一例报告
Heliyon. 2023 Jul 7;9(7):e18099. doi: 10.1016/j.heliyon.2023.e18099. eCollection 2023 Jul.
3
Pulmonary alveolar proteinosis following severe COVID - 19 infection: A case report.重症新型冠状病毒肺炎感染后并发肺泡蛋白沉积症:一例报告
Respir Med Case Rep. 2024 Mar 30;49:102017. doi: 10.1016/j.rmcr.2024.102017. eCollection 2024.
4
Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report.偏远地区肺泡蛋白沉积症的联合治疗模式:一例报告。
BMC Pulm Med. 2019 Mar 12;19(1):61. doi: 10.1186/s12890-019-0822-x.
5
A case report of Covid-19 in an autoimmune pulmonary alveolar proteinosis: An association in tune with the times!自身免疫性肺泡蛋白沉积症合并新型冠状病毒肺炎一例报告:与时俱进的关联!
Respir Med Case Rep. 2023;42:101825. doi: 10.1016/j.rmcr.2023.101825. Epub 2023 Feb 27.
6
Pulmonary alveolar proteinosis - a crazy presentation of dyspnea.肺泡蛋白沉积症——一种呼吸困难的奇特表现。
Eur Clin Respir J. 2018 Dec 4;6(1):1552065. doi: 10.1080/20018525.2018.1552065. eCollection 2019.
7
[Pulmonary alveolar proteinosis].[肺泡蛋白沉积症]
Medicina (B Aires). 2021;81(2):301-303.
8
Alveolar Proteinosis in COVID-19: Clinical Case.新型冠状病毒肺炎相关的肺泡蛋白沉积症:临床病例
Case Rep Pulmonol. 2022 Oct 22;2022:1842566. doi: 10.1155/2022/1842566. eCollection 2022.
9
Elevated Serum Anti-GM-CSF Antibodies before the Onset of Autoimmune Pulmonary Alveolar Proteinosis in a Patient with Sarcoidosis and Systemic Sclerosis.结节病和系统性硬化症患者自身免疫性肺泡蛋白沉积症发病前血清抗GM-CSF抗体升高。
Tohoku J Exp Med. 2017 Sep;243(1):77-83. doi: 10.1620/tjem.243.77.
10
Pulmonary Alveolar Proteinosis due to Familial Myelodysplastic Syndrome with resolution after stem cell transplant.家族性骨髓增生异常综合征所致肺泡蛋白沉积症,干细胞移植后病情缓解
Autops Case Rep. 2022 May 13;12:e2021382. doi: 10.4322/acr.2021.382. eCollection 2022.

本文引用的文献

1
Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021.估计 2020 年和 2021 年有症状 COVID-19 后持续性疲劳、认知和呼吸症状群个体在全球的比例。
JAMA. 2022 Oct 25;328(16):1604-1615. doi: 10.1001/jama.2022.18931.
2
A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings.一项关于 COVID-19 后遗症和免疫的纵向研究:基线结果。
Ann Intern Med. 2022 Jul;175(7):969-979. doi: 10.7326/M21-4905. Epub 2022 May 24.
3
Inflammasome activation in infected macrophages drives COVID-19 pathology.
在被感染的巨噬细胞中激活炎症小体导致 COVID-19 病理学。
Nature. 2022 Jun;606(7914):585-593. doi: 10.1038/s41586-022-04802-1. Epub 2022 Apr 28.
4
Pulmonary macrophages and SARS-Cov2 infection.肺巨噬细胞与新型冠状病毒2型感染
Int Rev Cell Mol Biol. 2022;367:1-28. doi: 10.1016/bs.ircmb.2022.01.001. Epub 2022 Mar 31.
5
Autoimmunity is a hallmark of post-COVID syndrome.自身免疫是新冠后综合征的一个标志。
J Transl Med. 2022 Mar 16;20(1):129. doi: 10.1186/s12967-022-03328-4.
6
CT Lung Abnormalities after COVID-19 at 3 Months and 1 Year after Hospital Discharge.COVID-19 后 3 个月和 1 年出院后肺部 CT 异常。
Radiology. 2022 May;303(2):444-454. doi: 10.1148/radiol.2021211746. Epub 2021 Oct 5.
7
Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment.持续性 COVID-19 间质性肺病。皮质类固醇治疗的观察性研究。
Ann Am Thorac Soc. 2021 May;18(5):799-806. doi: 10.1513/AnnalsATS.202008-1002OC.
8
COVID-19 pneumonia: the great radiological mimicker.新冠肺炎:强大的影像学模仿者。
Insights Imaging. 2020 Nov 23;11(1):118. doi: 10.1186/s13244-020-00933-z.
9
Review of the Chest CT Differential Diagnosis of Ground-Glass Opacities in the COVID Era.COVID 时代肺部磨玻璃密度影的 CT 鉴别诊断综述
Radiology. 2020 Dec;297(3):E289-E302. doi: 10.1148/radiol.2020202504. Epub 2020 Jul 7.
10
Prevalence and healthcare burden of pulmonary alveolar proteinosis.肺泡蛋白沉积症的患病率和医疗负担。
Orphanet J Rare Dis. 2018 Jul 31;13(1):129. doi: 10.1186/s13023-018-0846-y.